What to do if you bought a medicine containing poor quality valsartan?

Medications | Photo by sam.lt

The Ministry of Health draws attention to patients taking drugs with the active ingredient valsartan. Some of the patients bought drugs that are already withdrawn from the market and the next time they will go to a pharmacy to offer a drug from another manufacturer with the same active substance.

According to Kristina Garuolienė, deputy minister of health active substance poor quality valsartan, which began after Spain began an urgent withdrawal procedure and shared this information with others Member States and the European Medicines Agency in accordance with established procedures. Based on this information, the National Agency for Drug Control (IERC) also launched a recall procedure for medications of poor quality of the Lithuanian pharmaceutical supply network, including pharmacies (information available on the IWT website: www.vvkt.lt). The role of pharmacies is very important in eliminating low quality drugs containing valsartan. In cases where the patient arrives and wants to return a poor quality product containing valsartan, the pharmacy must accept it as a pharmaceutical waste, including blister packs.

To prevent the patient from being interrupted or inconvenienced by another quality product A prescription of a non-prescription medication for a period of 30 days to an adult patient.

A pharmacy that replaces a product of poor quality and of similar quality and decides the cost of cost acquisition must take into account the fact that "We hope that the joint efforts will not prejudice the provision of high-quality medicines with valsartan and that pharmacies will take all necessary measures, "said Deputy Minister Kristina Garuolienė.

We also recommend that residents taking medications containing valsartan look to their attending physician to badess the need for this medication and other therapeutic alternatives.

Currently, the European Medicines Agency, with the participation of the Directorate for Medicines Care and National Drug Agencies of the EU Member States are conducting a broader review and evaluation of the group of Scartan drugs.